{"id":390422,"date":"2019-05-15T00:00:00","date_gmt":"2019-05-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0028-2019-biopharma-major-depressive-disorder-treatment-algorithms-claims-data-analysis-us-2019\/"},"modified":"2026-03-31T10:46:53","modified_gmt":"2026-03-31T10:46:53","slug":"algocg0028-2019-biopharma-major-depressive-disorder-treatment-algorithms-claims-data-analysis-us-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0028-2019-biopharma-major-depressive-disorder-treatment-algorithms-claims-data-analysis-us-2019\/","title":{"rendered":"Major Depressive Disorder | Treatment Algorithms | Claims Data Analysis | US | 2019"},"content":{"rendered":"<p>In the United States a plethora of pharmacological treatments from an array of drug classes are available to patients with major depressive disorder (<abbr title=\"major depressive disorder\">MDD<\/abbr>), a highly drug-treated condition. Though the <abbr title=\"major depressive disorder\">MDD<\/abbr> drug market is highly entrenched with generic therapies, <abbr title=\"major depressive disorder\">MDD<\/abbr> patients\u2019 heterogeneous responses to antidepressants and\/or atypical antipsychotics afford branded drugs (e.g., Trintellix [Lundbeck \/ Takeda], Rexulti [Otsuka \/ Lundbeck]) the opportunity to be introduced into the treatment paradigm, often as later-line therapies. Given <abbr title=\"major depressive disorder\">MDD<\/abbr>\u2019s highly crowded and competitive landscape, it is valuable for drug marketers and developers to understand how <abbr title=\"major depressive disorder\">MDD<\/abbr> patients are being treated using real-world data.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed <abbr title=\"major depressive disorder\">MDD<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr title=\"major depressive disorder\">MDD<\/abbr> patients?<\/li>\n<li>How has Lundbeck \/ Otsuka\u2019s Rexulti (brexpiprazole) been integrated into the treatment algorithm, and what is its source of business?<\/li>\n<li>What percentage of <abbr title=\"major depressive disorder\">MDD<\/abbr> patients receive Lundbeck \/ Takeda\u2019s Trintellix (vortioxetine) within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of <abbr title=\"major depressive disorder\">MDD<\/abbr> patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.<\/p>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Real world data: <\/strong>Longitudinal patient-level claims data analysis<\/p>\n<p><strong>Key companies:<\/strong> Allergan, Eli Lilly, Lundbeck, Otsuka, Sunovion, Takeda<\/p>\n<p><strong>Key drugs:<\/strong> Aripiprazole (Abilify, aripiprazole), citalopram (Celexa, generics), duloxetine (Cymbalta, generics), Fetzima, Latuda, Rexulti, Trintellix, Viibryd<\/p>\n<p><strong>Key analysis provided:<\/strong><\/p>\n<ul>\n<li>Brand\/therapy usage across longitudinal patient sample<\/li>\n<li>Newly diagnosed patient analysis<\/li>\n<li>Treatment initiation and progression<\/li>\n<li>Line of therapy analysis<\/li>\n<li>Combination therapy analysis<\/li>\n<li>Source of business for recently treated patients<\/li>\n<li>Persistency and compliance analysis<\/li>\n<li>Product-level patient flow charts<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390422","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-major-depressive-disorder","biopharma-therapy-areas-unipolar-depression","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390422","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390422\/revisions"}],"predecessor-version":[{"id":393547,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390422\/revisions\/393547"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390422"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}